Welcome to our dedicated page for Rocket Doctor AI news (Ticker: AIRDF), a resource for investors and traders seeking the latest updates and insights on Rocket Doctor AI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rocket Doctor AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rocket Doctor AI's position in the market.
Rocket Doctor AI (OTC: AIRDF) entered a definitive agreement to acquire 100% of Alea Health Holdings Ltd. on November 19, 2025. Consideration includes US$15,000 cash paid, 285,712 common shares (deemed CAD$0.70 each) and assumption of a US$180,000 SAFE note payable in US$22,500 monthly instalments. Alea’s conversational AI and voice-based mental‑health platform will be integrated with Rocket Doctor AI’s Global Library of Medicine to expand mental‑health capabilities and enter the UAE/GCC market.
Closing is subject to employment agreements, regulatory approvals including the CSE, and applicable shareholder approvals; securities will be issued under prospectus exemptions with hold periods and a 28‑month escrow schedule.
Rocket Doctor AI (OTC:AIRDF) granted an aggregate 831,356 restricted share units (RSUs) and 20,964 stock options to consultants and employees on Nov 7, 2025.
The Options are exercisable for one common share at an exercise price of C$0.82 per share for a three‑year term and are subject to vesting provisions and plan terms.
- RSU terms: 325,000 RSUs expire in two years; 506,356 RSUs expire in three years.
- Vesting: 203,000 RSUs vest immediately; 628,356 RSUs are subject to vesting provisions.
- All grants are subject to the company equity plans and applicable securities law hold periods.
Rocket Doctor (OTC:AIRDF) on Nov 5, 2025 announced four senior U.S. appointments to accelerate clinical operations, digital growth, and coast‑to‑coast expansion. New hires include Dr. Evan Ou as U.S. Medical Director, Dr. Sudha Kumar as U.S. MD Lead for Psychiatry, Dr. Mike Solemar as California MD Lead, and Jimmy Vannavong as Director of Growth. The hires target strengthened payer and community partnerships, expanded provider networks in key states, and data‑driven patient recruitment via AI-enabled marketing. The move follows recent payer credentialing in New York and California and aims to improve access in rural and underserved U.S. communities.
Rocket Doctor AI (OTC:AIRDF) announced engagement of Fundamental Research Corp for independent analyst coverage effective Oct 21, 2025.
FRC is described as a long‑standing independent small‑cap research firm with a 22‑year track record and coverage of 750+ companies; its reports are distributed via Reuters, Capital IQ, Bloomberg and by subscription.
Under the agreement FRC will deliver a full financial analysis including an Independent Analyst Rating, an initiating report, periodic updates and unlimited interim notes over an 18‑month term. The company paid FRC a fee of CAD$35,000 in connection with the engagement.
Rocket Doctor (OTC:AIRDF) announced on October 21, 2025 that its Rocket Doctor platform is now in-network with two additional U.S. payers, expanding coverage by approximately 6.5 million members across California and New York.
The agreements (signed on October 9 and 10, 2025) add ~2.7 million covered lives in California and ~3.8 million in New York, bringing Rocket Doctor’s total in-network reach to well over 13 million members. The contracts span commercial, Medicare Advantage, and Veterans coverage and aim to broaden access to AI-powered, physician-led primary, urgent, chronic and mental healthcare.
Rocket Doctor AI (OTC:AIRDF) engaged FN Media Group for a three-day news and digital media marketing campaign starting the week of October 20, 2025 for USD $14,085.
FN Media will use its proprietary traffic application plus Google/Yahoo digital ads. The firm and its directors do not own any interest in Rocket Doctor AI and are described as arm’s length. FN Media contact details and address are provided in the announcement.
Rocket Doctor AI (OTC: AIRDF) announced that its U.S. subsidiary Treatment.com, together with Rush River Research, received a US $2.0 million NIH SBIR Phase II grant awarded by the National Institute on Minority Health and Health Disparities.
The two-year award advances an AI-powered, culturally sensitive family medical history tool, provides Treatment with over $500,000 to enhance its Global Library of Medicine (GLM), and supports commercialization and integration across commercial platforms with usability and community testing focused initially on African-American communities.
Rocket Doctor AI (OTCQB: AIRDF), a healthcare technology company, will present at the 2025 CANTech Letter Conference in Toronto on October 9, 2025. CEO Dr. Essam Hamza and Rocket Doctor Inc. Founder Dr. William Cherniak will deliver their presentation at 2:30 PM ET in Track 1.
The presentation will showcase the company's AI-powered healthcare platform, which focuses on improving healthcare accessibility and patient outcomes through streamlined workflows and reduced administrative friction. The company's leadership will discuss their platform innovations, recent milestones, and growth strategy.
FAQ
What is the current stock price of Rocket Doctor AI (AIRDF)?
